An open-label, multicenter, phase II study evaluating the safety and efficacy of twice daily dosing of SOM230 [pasireotide] in patients with metastatic carcinoid tumours.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2012
At a glance
- Drugs Pasireotide (Primary)
- Indications Carcinoid tumour
- Focus Therapeutic Use
- 18 Aug 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 18 Aug 2009 Actual patient number (45) added as reported by ClinicalTrials.gov.
- 21 Apr 2008 Status changed from in progress to completed, as reported by Novartis.